203 related articles for article (PubMed ID: 23379430)
1. Characteristics of in-vitro phenotypes of glutamic acid decarboxylase 65 autoantibodies in high-titre individuals.
Chéramy M; Hampe CS; Ludvigsson J; Casas R
Clin Exp Immunol; 2013 Mar; 171(3):247-54. PubMed ID: 23379430
[TBL] [Abstract][Full Text] [Related]
2. GAD autoantibody epitope pattern after GAD-alum treatment in children and adolescents with type 1 diabetes.
Skoglund C; Chéramy M; Casas R; Ludvigsson J; Hampe CS
Pediatr Diabetes; 2012 May; 13(3):244-50. PubMed ID: 21848927
[TBL] [Abstract][Full Text] [Related]
3. GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response.
Chéramy M; Skoglund C; Johansson I; Ludvigsson J; Hampe CS; Casas R
Clin Immunol; 2010 Oct; 137(1):31-40. PubMed ID: 20580618
[TBL] [Abstract][Full Text] [Related]
4. Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial.
Axelsson S; Chéramy M; Akerman L; Pihl M; Ludvigsson J; Casas R
Diabetes Care; 2013 Nov; 36(11):3418-24. PubMed ID: 23863909
[TBL] [Abstract][Full Text] [Related]
5. Characterization of CD4+ T cells specific for glutamic acid decarboxylase (GAD65) and proinsulin in a patient with stiff-person syndrome but without type 1 diabetes.
Hänninen A; Soilu-Hänninen M; Hampe CS; Deptula A; Geubtner K; Ilonen J; Knip M; Reijonen H
Diabetes Metab Res Rev; 2010 May; 26(4):271-9. PubMed ID: 20503259
[TBL] [Abstract][Full Text] [Related]
6. Autoantibodies to N-terminally Truncated GAD65(96-585): HLA Associations and Predictive Value for Type 1 Diabetes.
Pöllänen PM; Härkönen T; Ilonen J; Toppari J; Veijola R; Siljander H; Knip M
J Clin Endocrinol Metab; 2022 Feb; 107(3):e935-e946. PubMed ID: 34747488
[TBL] [Abstract][Full Text] [Related]
7. Stiff-person syndrome (SPS) and anti-GAD-related CNS degenerations: protean additions to the autoimmune central neuropathies.
Ali F; Rowley M; Jayakrishnan B; Teuber S; Gershwin ME; Mackay IR
J Autoimmun; 2011 Sep; 37(2):79-87. PubMed ID: 21680149
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies to N-terminally truncated GAD improve clinical phenotyping of individuals with adult-onset diabetes: Action LADA 12.
Achenbach P; Hawa MI; Krause S; Lampasona V; Jerram ST; Williams AJK; Bonifacio E; Ziegler AG; Leslie RD;
Diabetologia; 2018 Jul; 61(7):1644-1649. PubMed ID: 29619531
[TBL] [Abstract][Full Text] [Related]
9. Neuronal surface and glutamic acid decarboxylase autoantibodies in Nonparaneoplastic stiff person syndrome.
Chang T; Alexopoulos H; McMenamin M; Carvajal-González A; Alexander SK; Deacon R; Erdelyi F; Szabó G; Lang B; Blaes F; Brown P; Vincent A
JAMA Neurol; 2013 Sep; 70(9):1140-9. PubMed ID: 23877118
[TBL] [Abstract][Full Text] [Related]
10. Humoral and cellular autoimmune responses in stiff person syndrome.
Lohmann T; Londei M; Hawa M; Leslie RD
Ann N Y Acad Sci; 2003 Sep; 998():215-22. PubMed ID: 14592879
[TBL] [Abstract][Full Text] [Related]
11. GAD autoantibody affinity in adult patients with latent autoimmune diabetes, the study participants of a GAD65 vaccination trial.
Krause S; Landherr U; Agardh CD; Hausmann S; Link K; Hansen JM; Lynch KF; Powell M; Furmaniak J; Rees-Smith B; Bonifacio E; Ziegler AG; Lernmark A; Achenbach P
Diabetes Care; 2014 Jun; 37(6):1675-80. PubMed ID: 24598244
[TBL] [Abstract][Full Text] [Related]
12. Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes.
Tavira B; Barcenilla H; Wahlberg J; Achenbach P; Ludvigsson J; Casas R
J Diabetes Res; 2018; 2018():9391845. PubMed ID: 30009185
[TBL] [Abstract][Full Text] [Related]
13. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association.
Saiz A; Blanco Y; Sabater L; González F; Bataller L; Casamitjana R; Ramió-Torrentà L; Graus F
Brain; 2008 Oct; 131(Pt 10):2553-63. PubMed ID: 18687732
[TBL] [Abstract][Full Text] [Related]
14. Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.
Axelsson S; Chéramy M; Hjorth M; Pihl M; Akerman L; Martinuzzi E; Mallone R; Ludvigsson J; Casas R
PLoS One; 2011; 6(12):e29008. PubMed ID: 22174945
[TBL] [Abstract][Full Text] [Related]
15. Detection of autoantibodies against reactive oxygen species modified glutamic acid decarboxylase-65 in type 1 diabetes associated complications.
Khan MW; Banga K; Mashal SN; Khan WA
BMC Immunol; 2011 Mar; 12():19. PubMed ID: 21385406
[TBL] [Abstract][Full Text] [Related]
16. Association between high titers of glutamic acid decarboxylase antibody and epilepsy in patients with type 1 diabetes mellitus: A cross-sectional study.
Aguiar TS; Dantas JR; Cabral DB; Rêgo CCS; Zajdenverg L; Salles GF; Alves-Leon SV; Rodacki M; Lima MA
Seizure; 2019 Oct; 71():318-321. PubMed ID: 31525611
[TBL] [Abstract][Full Text] [Related]
17. GAD65 autoantibody characteristics in patients with co-occurring type 1 diabetes and epilepsy may help identify underlying epilepsy etiologies.
Liimatainen S; Honnorat J; Pittock SJ; McKeon A; Manto M; Radtke JR; ; Hampe CS
Orphanet J Rare Dis; 2018 Apr; 13(1):55. PubMed ID: 29636076
[TBL] [Abstract][Full Text] [Related]
18. Human B cells secreting immunoglobulin G to glutamic acid decarboxylase-65 from a nondiabetic patient with multiple autoantibodies and Graves' disease: a comparison with those present in type 1 diabetes.
Tremble J; Morgenthaler NG; Vlug A; Powers AC; Christie MR; Scherbaum WA; Banga JP
J Clin Endocrinol Metab; 1997 Aug; 82(8):2664-70. PubMed ID: 9253351
[TBL] [Abstract][Full Text] [Related]
19. Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition.
Daw K; Ujihara N; Atkinson M; Powers AC
J Immunol; 1996 Jan; 156(2):818-25. PubMed ID: 8543838
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial.
Elding Larsson H; Lundgren M; Jonsdottir B; Cuthbertson D; Krischer J;
Pediatr Diabetes; 2018 May; 19(3):410-419. PubMed ID: 29171140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
